Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The pooled prevalence of GERD in the Indian population is 15.6 %
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated